The US Food and Drug Administration (FDA) has granted clearance for Endogena Therapeutics’ investigational new drug application to treat geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD).
The FDA clearance will enable Endogena to progress with the clinical investigation of EA-2351.
Estimated to affect 9% of the population older than 45 years, AMD is an eye disease that can blur the central vision and is a leading cause of irreversible vision loss.
